Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2018-07

    • Bi-Layer Wound Dressings: Tranexamic Acid and NO for Hemosta

    2026-07-06

    Bi-Layer Wound Dressings: Tranexamic Acid and Nitric Oxide for Rapid Hemostasis and Infection Control

    Study Background and Research Question

    Traumatic injuries frequently result in life-threatening hemorrhage and high susceptibility to wound infections. Hemorrhagic instability accounts for up to 50% of early trauma-related deaths, while infection remains the second leading cause of mortality within days of injury. Traditional wound dressings often address either bleeding or infection, but rarely both, leaving a critical gap in emergency wound care. Tranexamic acid (TXA), a well-established antifibrinolytic agent, is known for its ability to stabilize clots by inhibiting fibrinolysis, but its integration into advanced wound dressings remains underexplored. The reference study set out to design a multifunctional wound dressing capable of achieving both immediate hemostasis and potent antibacterial action, leveraging the combined properties of TXA, a nitric oxide (NO) donor, and propolis.

    Key Innovation from the Reference Study

    The central innovation of the study is the fabrication of a bi-layer wound dressing—termed the TXA–SNAP–propolis (T-SP) system—that strategically combines three bioactive agents. The wound-facing layer is composed of TXA suspended in a resinous bed of propolis, while the base layer incorporates S-nitroso-N-acetylpenicillamine (SNAP), a nitric oxide donor, within a Carbosil® polymer matrix. This configuration enables the dressing to address two critical challenges: the TXA-propolis surface provides rapid clot stabilization and local antibacterial action, while the NO-releasing base sustains antimicrobial protection during the initial wound healing phases. The integration of TXA into the adhesive, antibacterial matrix of propolis achieves localized, dose-dependent inhibition of fibrinolysis, a mechanism previously validated in systemic and topical applications but not commonly realized in wound dressings. The study demonstrates that this bi-layered approach not only accelerates clot formation but also significantly reduces bacterial load, including multidrug-resistant strains (reference study).

    Methods and Experimental Design Insights

    The researchers developed the T-SP dressing using a layered fabrication process:
    • The wound-facing layer consisted of TXA distributed at variable concentrations (2.5%, 5.0%, and 7.5% by volume) on a bed of natural propolis, ensuring both adhesion and bioactivity.
    • The base layer was engineered with the NO donor SNAP, embedded in a Carbosil® (polycarbonate urethane-silicone copolymer) matrix, positioned to control the sustained release of NO away from the wound surface.
    To validate the clot-forming potential, a lactate dehydrogenase-based platelet adhesion assay was employed to quantify fibrin activation following application of the dressing. Scanning electron microscopy (SEM) provided ultrastructural evidence of clot morphology. Antibacterial performance was assessed by measuring reductions in colony-forming units (CFUs) for both Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii after exposure to the dressing. The main experimental endpoints included time-to-clot, fibrin network density, and bacterial viability.

    Protocol Parameters

    • Propolis concentration range: 2.5–7.5% (v/v) in the TXA-propolis wound-facing layer; optimal clotting observed at 7.5%.
    • NO-donor (SNAP) base: Incorporated in Carbosil® for sustained nitric oxide release; precise SNAP loading not disclosed, but intended for multi-hour release kinetics.
    • Tranexamic acid application: Uniform distribution within the resinous propolis matrix; concentration not quantified as mg/cm2, but paralleled clinically relevant topical use.
    • Platelet adhesion and fibrin activation: Measured after 15 minutes of dressing application.
    • Antibacterial challenge: CFU reduction for S. aureus and multidrug-resistant A. baumannii after incubation under simulated wound conditions.

    Core Findings and Why They Matter

    The T-SP dressing achieved immediate and robust clot formation, attributed to the antifibrinolytic action of TXA in the presence of propolis. Fibrin activation increased significantly within the first 15 minutes, with the highest effect seen in the formulation containing 7.5% propolis. SEM imaging revealed a dense, stabilized fibrin network, supporting the hypothesis that TXA effectively prevents lysis of the forming clot on the wound surface. In parallel, the dual antibacterial actions of NO and propolis led to near-complete eradication of both S. aureus (98.9 ± 1% reduction) and multidrug-resistant A. baumannii (99.4 ± 1% reduction). These results indicate that the bi-layer dressing can simultaneously manage the two most critical early-phase risks in trauma care: excessive bleeding and infection (reference study). The mechanism aligns with the established role of TXA as a competitive inhibitor of plasminogen activation, thereby limiting fibrinolysis at the site of application. The local delivery ensures high concentrations where needed, overcoming limitations of systemic administration and minimizing off-target effects. The synergy between TXA and propolis in the surface layer further supports clot integrity and provides a physical barrier against pathogens.

    Comparison with Existing Internal Articles

    Existing literature—including "Tranexamic Acid: Applied Antifibrinolytic Agent for Wound and Fibrinolysis Research"—has established the utility of Tranexamic Acid for both in vitro and in vivo hemostasis models, emphasizing its ability to stabilize clots and reduce bleeding time. The present study extends these findings by integrating TXA into a functional wound dressing matrix, offering a translational bridge from bench to bedside. Furthermore, the bi-layer concept aligns with the themes in "Antibacterial, Instant Clot-Forming Dressings via TXA–NO–Propolis Bi-Layers", but provides expanded protocol detail and quantitative antibacterial outcomes. Unlike prior work, which often evaluated TXA and NO donors in isolation, this study demonstrates the synergistic benefit of combining antifibrinolytic and antimicrobial mechanisms in a single dressing.

    Limitations and Transferability

    While the T-SP dressing exhibits promising hemostatic and antibacterial effects in vitro, several limitations should be considered. The study did not report in vivo efficacy, such as bleeding time reduction or infection outcomes in animal models, which are critical for clinical translation. The specific dosing and spatial distribution of TXA within the dressing matrix were not provided in standardized units, limiting direct comparison to clinical topical TXA protocols. Additionally, the stability and shelf-life of the combined bioactive agents under ambient conditions were not addressed. Transferability to human use will require further assessment of biocompatibility, long-term infection control, and manufacturing scalability. Nonetheless, the mechanistic rationale and robust in vitro evidence strongly support the value of this approach for emergency trauma care.

    Research Support Resources

    For researchers interested in modeling antifibrinolytic workflows or developing advanced wound healing assays, high-purity Tranexamic Acid is available as a research-grade reagent. Tranexamic Acid (SKU B1858) from APExBIO offers a validated tool for inhibition of fibrinolysis and clot stabilization protocols, supporting both mechanistic and translational studies. This product is suitable for integration into custom wound dressing matrices or for use in standardized plasmin-induced neutrophil adherence assays, as described in the reference study.